Amuvatinib

Amuvatinib is a multi-targeted inhibitor of receptor tyrosine kinases that inhibits c-Kit, platelet-derived growth factor receptor alpha (PDGFRalpha), and c-Met (IC50s = 10, 40, and 81 nM, respectively). It inhibits growth and induces apoptosis in prostate cancer cell lines, with additive effects achieved when combined with erlotinib (Cay-10483). Amuvatinib sensitizes cancer cells to radiation and chemotherapeutic compounds, in part by inhibiting homologous recombination.Formal Name: N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidin-4-yl-1-piperazinecarbothioamide. CAS Number: 850879-09-3. Synonyms: HPK56, MP470. Molecular Formula: C23H21N5O3S. Formula Weight: 447.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 20 mg/ml, DMF:PBS (pH 7.2)(1:3): 0.25 mg/ml, DMSO: 10 mg/ml. lambdamax: 244, 290, 315 nm. SMILES: S=C(N([H])CC1=CC=C(OCO2)C2=C1)N(CC3)CCN3C4=NC=NC5=C4OC6=C5C=CC=C6. InChi Code: InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32). InChi Key: FOFDIMHVKGYHRU-UHFFFAOYSA-N.